|
|
SCDMDG presents:
The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions
Tuesday April 19, 2016
Les Benet, Ph.D.
Professor, Dept. of Bioengineering and Therapeutic Sciences
University of California
San Francisco, CA
About The Meeting
Dr. Benet will examine the utility of the Biopharmaceutics Classification System (BCS) and help you understand the interplay of drug metabolizing enzymes and transport proteins as it relates to bioavailability and hepatic elimination. Dr. Benet will discuss:
- The Biopharmaceutics Classification System (BCS) - A system for predicting in vivo performance of drug products from in vitro measurements
- Slight modifications of such a Classification system can be useful in predicting:
- Routes of drug elimination
- The effects of efflux and absorptive transporters on oral drug absorption
- When transporter-enzyme interplay will yield clinically significant effects
- Transporter effects on post-absorptive systemic drug concentrations
- Drug-drug interaction potential via the relationship to enzyme-transporter interplay
Biography
Dr. Benet, Professor, Department of Biopharmaceutical Sciences, UCSF received honorary doctorates from eight universities. During 1986, Dr. Benet was a founder and first President of AAPS. In 1987 he was elected to membership in the Institute of Medicine of the U.S. National Academy of Sciences. His many awards include: AAPS Distinguished Pharmaceutical Scientist (1989); AACP Volwiler Research Achievement (1991); ASCPT Rawls-Palmer Award (1995); APhA Higuchi Research Prize (2000); AAPS Wurster Award in Pharmaceutics (2000); FIP Høst-Madsen Medal (2001). Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 20,000 times. His most recent work has addressed the interplay of metabolic enzymes and transport proteins as related to oral bioavailability and hepatic elimination, and the development of the Biopharmaceutics Drug Disposition Classification System (BDDCS). PSWC Research Achievement and CRS Career Achievement in Oral Drug Delivery (2004). His research interests, more than 530 publications and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. In 2004, he was awarded the Pharmaceutical Sciences World Congress Research Achievement Award and the CRS Career Achievement in Oral Drug Delivery Award. In 2007 he was selected as the UCSF Distinguished Clinical Research Lecturer and is still the only non-MD so honored. In 2010, he received the ASCPT Hunter Memorial Award in Therapeutics and in 2011 the ACCP Distinguished Investigator award. In 2012, the September issue of PHARMACEUTICAL RESEARCH was dedicated in his honor under the title "50 Years of Scientific Excellence and Still Going Strong" and he was made an honorary member of FIP. In March 2013, he was awarded the APhA Ebert Prize and the September issue of JOURNAL OF PHARMACEUTICAL SCIENCES was dedicated in his honor. In October, 2015 Dr. Benet was awarded the ISSX Scientific Achievement Award. He presently serves on the Boards of Directors of the American Foundation for Pharmaceutical Education, Impax Laboratories, and Medicines360, of which the latter, he chairs.
Space is Limited — Register Early to Guarantee Your Attendance!
Click here for a printable flyer.
Our April 2016 meeting is generously sponsored by:
Silver Sponsors
Bronze Sponsors
National University
For more information on sponsoring our April meeting, please refer to our sponsorship guidelines.
Prior presentations:
Note: slides are displayed in a new window, left-click to advance, right-click to go back.
Speaker |
PDF |
Topic |
Date |
Nicholas J. Schork, Ph.D. |
|
Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine |
September 15, 2015 |
Robert P. Hanzlik, Ph.D. |
|
Reactive Metabolites, Cellular Targets and Beyond |
April 28, 2015 |
J. Ernest Simpson, Ph.D. |
|
The Chemistry Of Wine |
October 28, 2014 |
Lawrence J. Marnett, Ph.D., F.C.P |
|
Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2 |
May 6, 2014 |
Lawrence J. Lesko, Ph.D., F.C.P. |
|
Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines |
May 14, 2013 |
Thomas Tozer, Ph.D. |
|
Pharmacokinetics of Protein Drugs |
October 23, 2012 |
Shujuan Chen |
|
Application of Animal Models for Human Glucuronidation |
October 23, 2012 |
Caroline Decker |
| The Use of Modified Bacterial CYPs for Metabolite Generation |
October 23, 2012 |
Mary Dwyer, Ph.D. |
| Cancer Therapeutics: A Novel Approach |
October 23, 2012 |
Justin Hoffman PharmD MS |
| Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum |
October 23, 2012 |
David A. Yee |
| Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients |
October 23, 2012 |
Nabil Hanna, Ph.D. |
|
The Discovery and Development of Rituxan |
April 10, 2012 |
Dr. Richard Kim |
|
Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance |
April 19, 2011 |
Dr. Jerry Galluppi |
|
Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist |
October 5, 2010 |
Dr. Dennis Smith |
|
Does drug metabolism hold its future in its own hands? |
April 27, 2010 |
Dr. Paul F. Hollenberg |
|
Mechanism-Based Inactivation of Human Cytochromes P450 |
October 6, 2009 |
Dr. Jack H. Dean Dr. Thomas Baillie |
|
Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective |
May 19, 2009 |
Eric Johnson, Ph.D. |
|
Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography |
September 30, 2008 |
Dr. Kenneth E. Thummel, Ph.D. |
|
Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics |
May 7, 2008 |
Dr. Anthony Lu, Ph.D. |
|
Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme? |
September 12, 2007 |
Dr. Scott Obach, Ph.D. |
|
Leveraging ADME Data In Metabolites In Safety Testing (MIST) |
April 18, 2007 |
Dr. Sidney Nelson, Ph.D. |
|
Drug Metabolism and Chemical Structural Alerts |
September 27, 2006 |
Richard B. Kim, MD |
|
Relevance and Utility of Transporters to Drug Discovery and Development |
September 21, 2005 |
Dr. Frederick P. Guengerich, Ph.D. |
|
Human Cytochrome P450 2A6 as a Case History: Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450 |
April 27, 2005 |
Dr. Leslie Benet, Ph.D. |
|
Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS |
September 29, 2004 |
Dr. Christopher A. Lipinski, Ph.D. |
|
ADME/Tox: How Low Can You Go And How Do You Recover? |
April 21, 2004 |
|
|
|